Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway
Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway have?
Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway has 44 citations in the OpenAlex counts ScholarIQ stores.
When was Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway published?
Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway has 2020 year in the ScholarIQ index.
What is the open-access status of Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway?
Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway has gold oa status in the ScholarIQ index.
What is the DOI of Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway?
The DOI for Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway is on the source record.
What is the PMID of Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway?
The PMID for Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway is on the source record.
What is the OpenAlex record for Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway?
The OpenAlex for Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway is on the source record.